Tetraphase wins $67M BARDA contract; Genzyme vet named CMO at bluebird;

@FierceBiotech: Researchers soup up patients' own immune cells to attack HIV. Story | Follow @FierceBiotech

@JohnCFierce: Fledgling Mnemosyne Pharmaceuticals snags a $5.4 million Series A for neuropsychiatric work. Release | Follow @JohnCFierce

@RyanMFierce: Not for those with arachnophobia: J&J to develop painkillers with spider venom in the mix. Article | Follow @RyanMFierce

@FierceMedDev: Edwards has received CE Mark for its EDWARDS INTUITY for those undergoing surgical aortic valve replacement. Release | Follow @FierceMedDev

> Tetraphase Pharmaceuticals says that the Biomedical Advanced Research and Development Authority (BARDA) has awarded it a contract worth up to $67 million for the development of TP-434, its lead antibiotic. Release

> Cambridge, MA-based bluebird bio has named Dr. David M. Davidson, a Genzyme vet, to the role of chief medical officer. Release

> Curis and Debiopharm say investigators have begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 inhibitor Debio 0932. Release

> Germany's Evotec AG and IR Pharma have forged a strategic alliance to offer integrated drug discovery solutions to pharma and biotech companies working in the respiratory disease field. Release

Pharma News

@FiercePharma: Yet another Ben Venue fumble: Sanofi's Genzyme unit recalls leukemia drug made at Ohio plant--Bloomberg. News | Follow @FiercePharma

> Wyeth puts $960M squeeze on Sun for Protonix launch. Article

> Sanofi yanks drug batch on CMO contamination fears. News

> Fake Avastin may not be the only counterfeit on doctors' shelves. More

Manufacturing News

> Hospira sees dim light at end of plant troubles. Piece

> FDA inspects three Merck KGaA plants along EU supply chain. Item

> West-Ward hit with warning letter over manufacturing, testing problems. Article

> U.S. market size, shortages lead to more counterfeits. Story

CRO News

> Complete Genomics soars after it snags sequencing deal with Mayo Clinic. Story

> Charles River sees signs of growth in latest assessment. More

> Quintiles to offer guidance on navigating Asian drug projects. News

> Ockham adds international oncology CRO ops in Nexus buyout. Article

> Report: Catalent wants $400M loan to back Aptuit unit buyout. Item

Vaccines News

> FDA says no to Novartis' Menveo vax for babies. Article

> Gynecological cancer vaccine enters clinical trials. More

> Research paving way to salmonella vaccine. Story

> IIL developing firsts for vaccines in India. News

> Sanofi's Shantha Biotechnics hopes to relaunch vaccine. Item

And Finally... New research by Rice University and the University of Texas MD Anderson Cancer Center indicates that a combination of drugs and carbon nanoparticles may enhance treatment for head-and-neck cancers, especially when combined with radiation therapy. Release